Docking Studies and Model Development of Tea Polyphenol Proteasome Inhibitors: Applications to Rational Drug Design

Proteins: Structure, Function and Genetics

Volumn 54, Issue 1, 2004, Pages 58-70

  Smith, David M ^a   Daniel, Kenyon G ^a   Wang, Zhigang ^b   Guida, Wayne C ^a,c   Chan, Tak Hang ^b   Dou, Q Ping ^a,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c ECKERD COLLEGE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 subunit; 20S proteasome; Chymotrypsin like activity; Computation; Drug discovery; EGCG; Green tea; Organic synthesis

Indexed keywords

AMIDE; CATECHIN; CHYMOTRYPSIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DRUG DERIVATIVE; EPIGALLOCATECHIN GALLATE; FLAVONOID; MULTIENZYME COMPLEX; PHENOL DERIVATIVE; POLYPHENOL; POLYPHENOLS; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN SUBUNIT;

ACYLATION; ARTICLE; BINDING SITE; CATALYSIS; CHEMICAL BOND; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; HYDROPHOBICITY; METABOLISM; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; TEA; VALIDATION PROCESS; X RAY DIFFRACTION;

AMIDES; BINDING SITES; CAMELLIA SINENSIS; CATECHIN; CHYMOTRYPSIN; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; FLAVONOIDS; MODELS, MOLECULAR; MULTIENZYME COMPLEXES; PHENOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN SUBUNITS;

EID: 0347417005     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.10504     Document Type: Article

References (41)

1. Goldberg AL. Functions of the proteasome: the lysis at the end of the tunnel. Science 1995;268:522-523.
2. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463-471.
3. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 1995;268:579-582.
4. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-758.
5. Dou QP, Nam S. Pharmacological proteasome inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000;10:1263-1272.
6. Dou QP, Li B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat 1999;2:215-223.
7. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;16:433-443.
8. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;5:1062-1075.
9. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997;272:12893-12896.
10. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
11. Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP, Sebti SM. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res 2001;61:1280-1284.
12. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-338.
13. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
14. Dou QP, Goldfarb RH. Evaluation of the proteasome inhibitor MLN-341 (PS-341). IDrugs 2002;5:828-834.
15. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001;311:543-548.
16. Ohno Y, Wakai K, Genka K, Ohmine K, Kawamura T, Tamakoshi A, Aoki R, Senda M, Hayashi Y, Nagao K, et al. Tea consumption and lung cancer risk: a case-control study in Okinawa, Japan. Jpn J Cancer Res 1995;86:1027-1034.
17. Zhong L, Goldberg MS, Gao YT, Hanley JA, Parent ME, Jin F. A population based case-control study of lung cancer and green tea consumption among women living in Shanghai, China. Epidemiology 2001;12:695-700.
18. Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, Blot WJ, Fraumeni JF Jr. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997;70:255-258.
19. Inoue M, Tajima K, Mizutani M, Iwata H, Iwase T, Miura S, Hirose K, Hamajima N, Tominaga S. Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. Cancer Lett 2001;167:175-182.
20. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H, Shimokawa R. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 1992;65:51-54.
21. Wang ZY, Huang MT, Ho CT, Chang R, Ma W, Ferraro T, Reuhl KR, Yang CS, Conney AH. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 1992;52:6657-6665.
22. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995;96:239-243.
23. Gupta S, Ahmad N, Mohan RR, Husain MM, Mukhtar H. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999;59:2115-2120.
24. Muto S, Yokoi T, Gondo Y, Katsuki M, Shioyama Y, Fujita K, Kamataki T. Inhibition of benzo[a]pyrene-induced mutagenesis by (-)-epigallocatechin gallate in the lung of rpsL transgenic mice. Carcinogenesis 1999;20:421-424.
25. Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999;125:589-597.
26. Yang CS. Tea and health. Nutrition 1999;15:946-949.
27. Ahmad N, Mukhtar H. Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev 1999;57:78-83.
28. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001;276:13322-13330.
29. Smith DM, Wang Z, Kazi A, Li LH, Chan TH, Dou QP. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med 2002;8:382-392.
30. Li L, Chan TH. Enantioselective synthesis of epigallocatechin-3-gallate (EGCG), the active polyphenol component from green tea. Org Lett 2001;3:739-741.
31. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242.
32. Morris GM, Goodsell DS, Halliday RS, R H, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-1662.
33. Dym O, Xenarios I, Ke H, Colicelli J. Molecular docking of competitive phosphodiesterase inhibitors. Mol Pharmacol 2002;61:20-25.
34. Rao MS, Olson AJ. Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach. Proteins 1999;34:173-183.
35. DeLano WL. The PyMOL Molecular Graphics System 2002. San Carlos, CA: DeLano Scientific; 2002.
36. Vicentini CB, Guarneri M, Andrisano V, Guccione S, Langer T, Marschhofer R, Chabin R, Edison AM, Huang X, Knight WB, Giori P. Potential of pyrazolooxadiazinone derivatives as serine protease inhibitors. J Enzyme Inhib 2001;16:15-34.
37. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 1996;271:7273-7276.
38. Antonov VK, Ivanina TV, Ivanova AG, Berezin TV, Levashov AV, Martinek K. Binding-catalysis relationship in alpha-chymotrypsin action as revealed from reversible inhibition study of phenylalkylboronic acids. FEBS Lett 1972;20:37-40.
39. da Graca Thrige D, Buur JR, Jorgensen FS. Substrate binding and catalytic mechanism in phospholipase C from Bacillus cereus: a molecular mechanics and molecular dynamics study. Biopolymers 1997;42:319-336.
40. Binda C, Angelini R, Federico R, Ascenzi P, Mattevi A. Structural bases for inhibitor binding and catalysis in polyamine oxidase. Biochemistry 2001;40:2766-2776.
41. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998;56:317-333.